Trial Profile
A Prospective, Multicenter, Randomized, Controlled, Phase ?Study of High-dose Nimotuzumab in Combined with Chemoradiotherapy Compared with Chemoradiotherapy alone for Local Advanced Esophageal Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2014
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 30 Jul 2014 Planned number of patients changed from 60 to 120.
- 30 Jul 2014 New trial record